Briakinumab

Bibliography

• Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004;3(2):121-8
   PubMedGoogle Scholar
• Valdimarsson H. The genetic basis of psoriasis. Clin Dermatol 2007;25(6):563-7
   PubMed Web of Science ®Google Scholar
• Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005;352(18):1899-912
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58(5):851-64
   PubMed Web of Science ®Google Scholar
• Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005;153(3):486-97
   PubMed Web of Science ®Google Scholar
• Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004;9(2):136-9
   PubMed Web of Science ®Google Scholar
• Pugashetti R, Koo J. Efalizumab discontinuation: a practical strategy. J Dermatolog Treat 2009;20:132-6
   PubMed Web of Science ®Google Scholar
• Rozenblit M, Lebwohl M. New biologics for psoriasis and psoriatic arthritis. Dermatol Ther 2009;22(1):56-60
   PubMed Web of Science ®Google Scholar
• Kimball AB, Gordon KB, Langley RG, et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008;144(2):200-7
   PubMed Web of Science ®Google Scholar
• Ding C, Xu J, Li J. ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases. Curr Opin Investig Drugs 2008;9(5):515-22
   PubMed Web of Science ®Google Scholar
• Kuus-Reichel K, Grauer LS, Karavodin LM, et al. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin Diagn Lab Immunol 1994;1(4):365-72
   PubMedGoogle Scholar
• Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol 2007;57(6):1059-68
   PubMed Web of Science ®Google Scholar
• Wysocka M, Kubin M, Vieira LQ, et al. Interleukin-12 is required for interferon-γ production and lethality in lipopolysaccharide-induced shock in mice. Eur J Immunol 1995;25(3):672-6
   PubMed Web of Science ®Google Scholar
• Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004;351(20):2069-79
   PubMed Web of Science ®Google Scholar
• Paulson S, Valdes J, Hruska M, Awni W. The pharmacokinetics of the fully human, interleukin-12/-23 monoclonal antibody (ABT-874) in normal healthy volunteers. J Am Acad Dermatol2009;60(3):AB168
   Google Scholar
• Efficacy and safety of ABT-874 in subjects with moderate to severe chronic plaque psoriasis. NCT00292396. NIH, 2008. Available from: http://clinicaltrials.gov/ct2/show/NCT00292396 [Last accessed 15 June 2009]
   Google Scholar
• Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease. NCT00562887. NIH, 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT005 62887?term=NCT00562887&rank=1 [Last accessed 15 June 2009]
   Google Scholar
• Open Label Continuation Study in Moderate to Severe Psoriasis. NCT00626002. NIH, 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00626002?term=NCT+00626002&rank=1 [Last accessed 15 June 2009]
   Google Scholar
• A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis. NCT00679731. NIH, 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00679731?show_locs=Y [Last accessed 15 June 2009]
   Google Scholar
• Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis. NIH. 2009. Available from: http://clinicaltrials.gov/ct2/results?term=NCT00710580 [Last accessed 15 June 2009]
   Google Scholar
• Bowman EP, Chackerian AA, Cua DJ. Rationale and safety of anti-interleukin-23 and anti-interleukin-17A therapy. Curr Opin Infect Dis 2006;19(3):245-52
   PubMed Web of Science ®Google Scholar
• de Jong R, Altare F, Haagen IA, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 1998;280(5368):1435-8
   PubMed Web of Science ®Google Scholar
• Cooper AM, Solache A, Khader SA. Interleukin-12 and tuberculosis: an old story revisited. Curr Opin Immunol 2007;19(4):441-7
   PubMed Web of Science ®Google Scholar
• Esther van de V, Ottenhoff TH. Human host genetic factors in mycobacterial and Salmonella infection: lessons from single gene disorders in IL-12/IL-23-dependent signaling that affect innate and adaptive immunity. Microbes Infect 2006;8(4):1167-73
   PubMed Web of Science ®Google Scholar
• MacLennan C, Fieschi C, Lammas DA, et al. Interleukin (IL)-12 and IL-23 are key cytokines for immunity against Salmonella in humans. J Infect Dis 2004;190(10):1755-7
   PubMed Web of Science ®Google Scholar
• Kimball AB, Zhong J, Valdes JM, Gordon K. Retreatment efficacy and long-term safety of the fully human, interleukin -12/-23 monoclonal antibody ABT-874 in the treatment of moderate to severe psoriasis: 48-week results from a phase II trial. J Am Acad Dermatol2009;60(3):AB168
   Google Scholar
• Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009;373(9664):633-40
   PubMed Web of Science ®Google Scholar
• Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356(6):580-92
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371(9625):1665-74
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371(9625):1675-84
   PubMed Web of Science ®Google Scholar
• Vergou T, Lima XT, Kimball AB. Targeting the IL-12/IL-23 cytokine family in the treatment of psoriatic disease. Expert Rev Dermatol 2008;3(4):11
   Google Scholar
• Gordon KB, Leonardi CL, Papp KA, et al. Maintenance of response and safety with the fully human IL-12/23 monocolonal antibody, ABT-874, in the treatment of moderate to severe plaque psoriasis: 24-week results from a Phase II trial 21st World Congress of Dermatology. Buenos Aires, Argentina 2007
   Google Scholar